Abstract:Elevated blood cholesterol is an established risk factor for coronary heart disease (CHD), and the basis for treatment is normalisation of LDL-cholesterol (LDL-C). If dietary measures fail, inhibitors of HMG-CoA reductase (HMGR) potently lower LDL-C, and have been shown to reduce morbidity and mortality for CHD. New investigational drugs, reviewed herein, will address other medical needs, such as inhibiting cholesterol synthesis without affecting the synthesis of other essential molecules (e.g., ubiquinone, dolichol, etc.), inhibiting biliary and dietary cholesterol absorption, lowering Lp(a), elevating HDL and/or stimulating reverse cholesterol transport, and directly interacting with numerous arterial wall proteins involved in atherogenesis. Potent and specific drugs can best answer important questions about whether elevating HDL-C (or other apoAl-containing particles) or lowering Lp(a) is beneficial, much in the same way that HMGR inhibitors have answered questions about the merits of LDL lowering. Arterial wall targets (e.g., ACAT, VCAM, 15-LO), aimed primarily at CHD patients with normal lipoprotein profiles, will likely be more challenging with regard to drug development. Theoretically, such drugs must achieve sufficient concentrations in the bloodstream so as to result in appreciable uptake/accumulation in arterial lesions, but yet possess an acceptable margin of safety. Moreover, surrogate markers for determining clinical effectiveness, which at present are limited to expensive, specialised techniques, must be identified. Whom and when to treat remain to be established, and drugs affecting targets at the arterial wall will likely have to demonstrate an additive or unique activity compared to HMGR inhibitors. Thus, refined methods of lesion assessment will become essential for all approaches, both lipoprotein and nonlipoprotein-based, to obtain a clinical indication for CHD in man.

Impact of natural products on the cholesterol transporter ABCA1

Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease

Recent developments in the regulation of cholesterol transport by natural molecules

Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs

Role of ABCA1 in Atherosclerosis: Novel Mutations and Potential Plant-derived Therapies

Natural products for the prevention and treatment of cholestasis: A review

Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function

Molecular basis of cholesterol efflux via ABCG subfamily transporters

Effect of physical activity on prevention and treatment of atherosclerosis: focus on activity of ABCG5 and ABCG8 genes

Section Review—Cardiovascular & Renal: Emerging Therapies in Atherosclerosis

Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy: Recent Progress and Future Perspectives

Exploring Phytochemical Mechanisms in the Prevention of Cholesterol Dysregulation: A Review

Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products

Traditional Chinese medicine and plant-derived natural products in regulating triglyceride metabolism: Mechanisms and therapeutic potential

The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism

A Review: Molecular Mechanism of Regulation of ABCA1 Expression.

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis.

Erythrodiol, an Olive Oil Constituent, Increases the Half-Life of ABCA1 and Enhances Cholesterol Efflux from THP-1-Derived Macrophages

Native LDL Upregulation of ATP-Binding Cassette Transporter-1 in Human Vascular Endothelial Cells

Identifying the natural products in the treatment of atherosclerosis by increasing HDL-C level based on bioinformatics analysis, molecular docking, and in vitro experiment